Pompe Disease Treatment Market faces both strong opportunities and significant challenges. The rarity of the condition, high treatment costs, complex administration requirements, and need for lifelong management can create barriers to broader access, while healthcare systems increasingly focus on demonstrating the long-term value of rare-disease therapies.

Another challenge is the need for continuous clinical monitoring. Pompe disease can progress differently among patients, requiring healthcare professionals to assess respiratory function, muscle strength, mobility, and other disease-related outcomes when evaluating treatment effectiveness.

At the same time, the emergence of next-generation ERTs, combination therapies, and investigational gene therapies creates substantial growth opportunities. Research into more durable and targeted treatment approaches could eventually reshape the therapeutic landscape and reduce some of the limitations associated with conventional treatment.

Overall, the future of the market will depend on advances in early diagnosis, therapeutic innovation, patient access, and reimbursement. As the pipeline expands and rare-disease care becomes more specialized, companies with differentiated therapies and strong clinical evidence are positioned to play an important role in the evolving Pompe disease treatment landscape.